These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 29426605)

  • 41. Immunohistochemistry as a reliable method for detection of BRAF-V600E mutation in melanoma: a systematic review and meta-analysis of current published literature.
    Anwar MA; Murad F; Dawson E; Abd Elmageed ZY; Tsumagari K; Kandil E
    J Surg Res; 2016 Jun; 203(2):407-15. PubMed ID: 27363650
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Liquid Profiling of Circulating Tumor DNA in Plasma of Melanoma Patients for Companion Diagnostics and Monitoring of BRAF Inhibitor Therapy.
    Haselmann V; Gebhardt C; Brechtel I; Duda A; Czerwinski C; Sucker A; Holland-Letz T; Utikal J; Schadendorf D; Neumaier M
    Clin Chem; 2018 May; 64(5):830-842. PubMed ID: 29483107
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): results of a phase 3, open-label, randomised trial.
    Grob JJ; Amonkar MM; Karaszewska B; Schachter J; Dummer R; Mackiewicz A; Stroyakovskiy D; Drucis K; Grange F; Chiarion-Sileni V; Rutkowski P; Lichinitser M; Levchenko E; Wolter P; Hauschild A; Long GV; Nathan P; Ribas A; Flaherty K; Sun P; Legos JJ; McDowell DO; Mookerjee B; Schadendorf D; Robert C
    Lancet Oncol; 2015 Oct; 16(13):1389-98. PubMed ID: 26433819
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Circulating tumour DNA: analytical aspects and clinical applications for metastatic melanoma patients.
    Herbreteau G; Vallée A; Knol AC; Théoleyre S; Quéreux G; Khammari A; Dréno B; Denis MG
    Ann Biol Clin (Paris); 2017 Dec; 75(6):619-630. PubMed ID: 29192597
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Genomic Analysis of Circulating Tumor DNA Using a Melanoma-Specific UltraSEEK Oncogene Panel.
    Gray ES; Witkowski T; Pereira M; Calapre L; Herron K; Irwin D; Chapman B; Khattak MA; Raleigh J; Hatzimihalis A; Cebon J; Sandhu S; McArthur GA; Millward M; Ziman M; Dobrovic A; Wong SQ
    J Mol Diagn; 2019 May; 21(3):418-426. PubMed ID: 30731208
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Isolation and Quantification of Plasma Circulating Tumor DNA from Melanoma Patients.
    Marsavela G; Reid A; Gray ES; Calapre L
    Methods Mol Biol; 2021; 2265():247-263. PubMed ID: 33704720
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Molecular platforms utilized to detect BRAF V600E mutation in melanoma.
    Curry JL; Torres-Cabala CA; Tetzlaff MT; Bowman C; Prieto VG
    Semin Cutan Med Surg; 2012 Dec; 31(4):267-73. PubMed ID: 23174497
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Use of circulating tumoral DNA to guide treatment for metastatic melanoma.
    Herbreteau G; Charpentier S; Vallée A; Denis MG
    Pharmacogenomics; 2019 Dec; 20(18):1259-1270. PubMed ID: 31596166
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Controversies in Intrapatient Melanoma BRAFV600E Mutation Status.
    Riveiro-Falkenbach E; Santos-Briz A; Ríos-Martín JJ; Rodríguez-Peralto JL
    Am J Dermatopathol; 2017 Apr; 39(4):291-295. PubMed ID: 28323782
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Is it good or bad to find a BRAF mutation?
    Flaherty KT
    J Clin Oncol; 2011 Apr; 29(10):1229-30. PubMed ID: 21343552
    [No Abstract]   [Full Text] [Related]  

  • 51. BRAF and KIT somatic mutations are present in amelanotic melanoma.
    Massi D; Pinzani P; Simi L; Salvianti F; De Giorgi V; Pizzichetta MA; Mirri F; Steffan A; Orlando C; Santucci M; Canzonieri V
    Melanoma Res; 2013 Oct; 23(5):414-9. PubMed ID: 23938765
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Molecular characterization of a selected cohort of patients affected by pulmonary metastases of malignant melanoma: Hints from BRAF, NRAS and EGFR evaluation.
    Ulivieri A; Cardillo G; Manente L; Paone G; Mancuso AP; Vigna L; Di Stasio E; Gasbarra R; Girlando S; Leone A
    Oncotarget; 2015 Aug; 6(23):19868-79. PubMed ID: 26305188
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A Case of Giant Primary Dermal Melanoma with BRAF V600E Mutation.
    Imamura T; Nakamura Y; Teramoto Y; Sato S; Asami Y; Arai E; Yamamoto A
    Acta Derm Venereol; 2016 Aug; 96(6):840-1. PubMed ID: 26984828
    [No Abstract]   [Full Text] [Related]  

  • 54. Method of mutation analysis may contribute to discrepancies in reports of (V599E)BRAF mutation frequencies in melanocytic neoplasms.
    Miller CJ; Cheung M; Sharma A; Clarke L; Helm K; Mauger D; Robertson GP
    J Invest Dermatol; 2004 Nov; 123(5):990-2. PubMed ID: 15482489
    [No Abstract]   [Full Text] [Related]  

  • 55. Concordance in BRAF V600E status over time in malignant melanoma and corresponding metastases.
    Nielsen LB; Dabrosin N; Sloth K; Bønnelykke-Behrndtz ML; Steiniche T; Lade-Keller J
    Histopathology; 2018 Apr; 72(5):814-825. PubMed ID: 29119584
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Clinicopathological relevance of BRAF mutations in human cancer.
    Pakneshan S; Salajegheh A; Smith RA; Lam AK
    Pathology; 2013 Jun; 45(4):346-56. PubMed ID: 23594689
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Circulating biomarkers in malignant melanoma.
    Alegre E; Sammamed M; Fernández-Landázuri S; Zubiri L; González Á
    Adv Clin Chem; 2015; 69():47-89. PubMed ID: 25934359
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Allele frequencies of BRAFV600 mutations in primary melanomas and matched metastases and their relevance for BRAF inhibitor therapy in metastatic melanoma.
    Satzger I; Marks L; Kerick M; Klages S; Berking C; Herbst R; Völker B; Schacht V; Timmermann B; Gutzmer R
    Oncotarget; 2015 Nov; 6(35):37895-905. PubMed ID: 26498143
    [TBL] [Abstract][Full Text] [Related]  

  • 59. BRAF mutation-positive folliculotropic metastatic melanoma.
    Brick KE; Halling KC; Khan YK; Peters MS
    Am J Dermatopathol; 2013 Jul; 35(5):609-12. PubMed ID: 23715079
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [THE BRAF MUTATION AND THE POSSIBILITIES OF UVEAL MELANOMA METASTASING PROGNOSTIC MARKERS IDENTIFICATION].
    Horkovičová K; Markus J; Krčová I; Babál P; Kobzová D; Smolková B
    Cesk Slov Oftalmol; 2016; 72(4):149-156. PubMed ID: 27860480
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.